Archive | 2021
Tofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study
Abstract
This non-randomized controlled study aimed to assess the efficacy of\ntofacitinib in reducing the risk of invasive mechanical ventilation or\ndeath in patients with COVID-19. Patients with COVID-19 associated with\nreduced oxygen saturation, increased C-reactive protein (≥50 mg/L),\nand/or persisting fever were recruited. Tofacitinib was administered in\naddition to standard of care therapy. Study outcomes were evaluated\nseparately in the groups of patients with oxygen saturation at rest\n≤93% and >93%. Hazard ratios (HR) with 95% confidence\nintervals (CI) were calculated using Cox regression analysis adjusted\nfor inverse propensity score weighting. Overall, 384 patients with\nCOVID-19 (212 males; median age 60 years) were included in our study and\nwere treated with tofactinib (n=131) or standard of care alone (n=253).\nThe percentages of patients who started mechanical ventilation or died\nduring hospitalization in the tofacitinib and control groups were 12.5%\n(9/72) vs. 14.1% (26/185) among patients who required respiratory\nsupport (HR 0.92, 95% CI 0.33-2.56), and 1.7% (1/59) vs. 4.4% (3/68)\nin those with normal oxygen saturation (HR 0.83; 95 CI 0.07-9.44).\nTofacitinib did not reduce the risk of invasive mechanical ventilation\nor death in patients with COVID-19, although the analysis of these\noutcomes favored tofacitinib.